Search research articles
Contact Us
Filters
Showing results (1-10 of 48) with videos related to
Page
of 5
Sort By:
Expert Opinion on Biological Therapy
|
July 15, 2014
Clinical experience with ramucirumab : outcomes in breast cancer
Geraldine O'Sullivan Coyne, Mauricio Burotto
Expert Opinion on Biological Therapy
|
July 11, 2017
MABp1 for the treatment of colorectal cancer
Geraldine O'Sullivan Coyne, Mauricio Burotto
Human Vaccines & Immunotherapeutics
|
December 9, 2014
Adding fuel to the fire: immunogenic intensification
Geraldine O'Sullivan Coyne, James L Gulley
Hepatic Oncology
|
September 8, 2018
Our experts highlight the most important research articles across the spectrum of topics relevant to the field of hepatic oncology
Geraldine O'Sullivan Coyne, Tim F Greten
Hepatic Oncology
|
September 8, 2018
Immune play: defending the liver
Geraldine O'Sullivan Coyne, Tim F Greten
JAMA Oncology
|
September 10, 2020
Posterior Subglottic Mass in a Patient With a History of Rectal Adenocarcinoma and Lung Metastases
Forrest Craig, Geraldine O'Sullivan Coyne, Clint T Allen
Expert Opinion on Drug Safety
|
October 28, 2014
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma
Mauricio Burotto, Syed Abbas Ali, Geraldine O'Sullivan Coyne
Chinese Clinical Oncology
|
September 27, 2015
An overview of the NCI precision medicine trials-NCI MATCH and MPACT
Khanh Do, Geraldine O'Sullivan Coyne, Alice P Chen
Current Problems in Cancer
|
April 5, 2017
Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH
Geraldine O'Sullivan Coyne, Naoko Takebe, Alice P Chen
Expert Opinion on Drug Safety
|
June 15, 2012
Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer
Geraldine O'Sullivan Coyne, Janice Walsh, Catherine M Kelly
Page
of 5
Search research articles
Search
Showing results (1-10 of 48) with videos related to
Sort By:
Page
of 5
Expert Opinion on Biological Therapy
|
July 15, 2014
Clinical experience with ramucirumab : outcomes in breast cancer
Geraldine O'Sullivan Coyne, Mauricio Burotto
Expert Opinion on Biological Therapy
|
July 11, 2017
MABp1 for the treatment of colorectal cancer
Geraldine O'Sullivan Coyne, Mauricio Burotto
Human Vaccines & Immunotherapeutics
|
December 9, 2014
Adding fuel to the fire: immunogenic intensification
Geraldine O'Sullivan Coyne, James L Gulley
Hepatic Oncology
|
September 8, 2018
Our experts highlight the most important research articles across the spectrum of topics relevant to the field of hepatic oncology
Geraldine O'Sullivan Coyne, Tim F Greten
Hepatic Oncology
|
September 8, 2018
Immune play: defending the liver
Geraldine O'Sullivan Coyne, Tim F Greten
JAMA Oncology
|
September 10, 2020
Posterior Subglottic Mass in a Patient With a History of Rectal Adenocarcinoma and Lung Metastases
Forrest Craig, Geraldine O'Sullivan Coyne, Clint T Allen
Expert Opinion on Drug Safety
|
October 28, 2014
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma
Mauricio Burotto, Syed Abbas Ali, Geraldine O'Sullivan Coyne
Chinese Clinical Oncology
|
September 27, 2015
An overview of the NCI precision medicine trials-NCI MATCH and MPACT
Khanh Do, Geraldine O'Sullivan Coyne, Alice P Chen
Current Problems in Cancer
|
April 5, 2017
Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH
Geraldine O'Sullivan Coyne, Naoko Takebe, Alice P Chen
Expert Opinion on Drug Safety
|
June 15, 2012
Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer
Geraldine O'Sullivan Coyne, Janice Walsh, Catherine M Kelly
Page
of 5